RS Oncology Reports New Preclinical Evidence Show RSO-021 Could Halt and/or Revert the Advancement of Severe Mesotheliomas
During the IASLC 2023 World Conference on Lung Cancer held in Singapore, RS Oncology, a biotech firm at the clinical trial phase, which is innovatively creating treatments to eliminate mesothelioma and various other ailments, has participated in a joint study recently presenting innovative preclinical findings. The company's unique treatment, RSO-021, a first-in-class class inhibitor of the antioxidant protein PRX3, displayed its capability to counteract numerous characteristics tied to the rapid progression of mesothelioma tumors.
👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Dr. Dean Fennell's presentation revealed a collaborative effort between RS Oncology and various prominent research establishments, like the University of Leicester and the University of Vermont Cancer Center's Cunniff Laboratory. Mesotheliomas can evolve from a less aggressive epithelioid cancer type to a highly aggressive sarcomatoid form.
The research group at the University of Leicester, guided by Dr. Fennell, utilized biphasic mesotheliomas as a model with both epithelioid and sarcomatoid characteristics, performing a geospatial investigation of patient tissues to discover the molecular markers linked with the histological areas.
Through the integration of advanced spatial analytic tools and machine learning methods, the team discovered that the highly aggressive sarcomatoid regions showcased unique molecular markers that prompted pro-tumor pathways, medication resistance, and heightened metastatic capability.
These results were confirmed within an independent group of 150 mesothelioma patient tissues. Worth mentioning, tumor areas containing sarcomatoid tissue displayed indications of heightened resistance to oxidative stress.
“Sarcomatoid tumors proved to be highly resistant to anti-cancer treatments, leaving many patients with no remaining treatment alternatives. We believe our findings may have exposed a potentially treatable 'Achilles' heel' against this horrific disease,” stated Dr. Fennell, the main presenter of the research. “The opportunity to use RSO-021 to treat these tumors and revert them back to epithelioid cancers could postpone or even prevent the development of the most aggressive characteristics linked with mesothelioma. Also, RSO-021 could potentially make them more receptive to other treatments."
👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.
According to the data provided by the Synapse Database, As of September 18, 2023, there are 148 investigational drugs for the 50S subunit target, including 186 indications, 159 R&D institutions involved, with related clinical trials reaching 2217，and as many as 56 patents.
RSO-021 is a synthetic peptide drug developed by RS Oncology LLC. It has shown potential in treating various cancers and other diseases related to the respiratory, digestive, endocrine, and urogenital systems. While still in the early stages of development, RSO-021's orphan drug status highlights its potential to address unmet medical needs in rare diseases. Further research and clinical trials will be necessary to determine its safety and efficacy.
